UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT Pursuant
to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 12, 2016
CELGENE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware | 001-34912 | 22-2711928 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
86 Morris Avenue, Summit, New Jersey | 07901 |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (908) 673-9000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 8.01 OTHER EVENTS
On September 12, 2016, Celgene Corporation issued a press release providing an interim update on the ongoing phase 1b CD-001 study exploring the effects of oral GED-0301 (mongersen) on both endoscopic and clinical outcomes in patients with active Crohn’s disease. Attached hereto and incorporated herein by reference as Exhibit 99.1 is the press release announcement.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit 99.1 – Press Release dated September 12, 2016
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CELGENE CORPORATION | ||
Date: September 12, 2016 | By: | /s/ Peter N. Kellogg |
Peter N. Kellogg | ||
Executive Vice President and | ||
Chief Financial Officer | ||
(principal financial and accounting officer) |
EXHIBIT INDEX
Exhibit No. | Description | |
99.1 | Press Release dated September 12, 2016 |